Jazz Pharmaceuticals plc
JAZZJazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Drugs in Pipeline
48
Phase 3 Programs
27
Upcoming Catalysts
8
Next Catalyst
Feb 12, 2026
4dMarket Overview
Stock performance and market intelligence
8 upcoming, 1 past
FDA PDUFA Date JZP-458 (priority)
For Acute Lymphoblastic Leukemia (ALL). NDA filing. Extracted from SEC filing: 8-K
SourceFDA PDUFA Date (priority review)
AI-extracted from news: Jazz sells priority review voucher for $200M, scoring highest price in a decade
SourceZanidatamab Phase 3 Results Expected
Primary completion for Zanidatamab trial (NCT05152147) in Gastric Neoplasms
SourceTislelizumab Phase 3 Results Expected
Primary completion for Tislelizumab trial (NCT05152147) in Gastric Neoplasms
SourceCapecitabine Phase 3 Results Expected
Primary completion for Capecitabine trial (NCT05152147) in Gastric Neoplasms
SourceDordaviprone (ONC201) Phase 3 Results Expected
Primary completion for Dordaviprone (ONC201) trial (NCT05580562) in H3 K27M
SourceLurbinectedin Phase 2 Results Expected
Primary completion for Lurbinectedin trial (NCT05734066) in Refractory Ewing Sarcoma
SourceZanidatamab Phase 2 Results Expected
Primary completion for Zanidatamab trial (NCT06695845) in Breast Cancer
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Sativex
Multiple Sclerosis
Nabiximols
Pain
Brincidofovir
Adenovirus Infection
Xyrem®
Fibromyalgia
Xyrem
Narcolepsy
Dordaviprone (ONC201)
H3 K27M
Sodium Oxybate
Essential Tremor
IM JZP-458
Acute Lymphoblastic Leukemia
GW-1000-02
Pain
Sodium Oxybate & 6 Tablets
Fibromyalgia
Zanidatamab
HER2-positive Breast Cancer
Gemcitabine
Metastatic HER2-positive Breast Cancer
Capecitabine
Gastric Neoplasms
CPX-351
Acute Myeloid Leukemia (AML)
Pembrolizumab
Biliary Tract Cancer
7+3 (cytarabine and daunorubicin)
High Risk Acute Myeloid Leukemia
Defibrotide
Severe Hepatic Veno-Occlusive Disease
experimental anti-anxiety drug
Anxiety Disorder
GW-2000-02
Pain
Xyrem (sodium oxybate) oral solution
Fibromyalgia
a benzodiazepine drug
Anxiety Disorder
JZP-258
Idiopathic Hypersomnia
THC Alone
Palliative Care
GWP42003-P
Epilepsy
GWP42003-P 20 mg/kg/day Dose
Epilepsy
Sativex®
Pain
JZP-110
Obstructive Sleep Apnea
Suvecaltamide
Parkinson Disease
Dociparstat sodium
Acute Myeloid Leukemia
Palbociclib
HER2+/HR+ Breast Cancer
Lurbinectedin
Refractory Ewing Sarcoma
GWP42006
Epilepsy
ZW25 (Zanidatamab)
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
asparaginase Erwinia chrysanthemi
Acute Lymphoblastic Leukemia
GWP42003
Schizophrenia
Evorpacept
HER2-expressing Cancers
Clobazam
Epilepsy
Daunorubicin
Acute Myeloid Leukemia
GWP42004
Dyslipidemias
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Colorectal Neoplasms
CX-8998
Epilepsy
JZP385
Essential Tremor
Clonazepam
Epilepsy
GWP42003-P 5 mg/kg/day Dose
Epilepsy
Standard of Care
Graft-versus-host Disease
Intensive Salvage Therapy
Acute Myeloid Leukemia
JZP150
Post Traumatic Stress Disorder
ADX-N05
Narcolepsy
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Sativex | Phase 3 | Multiple Sclerosis | - |
Nabiximols | Phase 3 | Pain | - |
Brincidofovir | Phase 3 | Adenovirus Infection | - |
Xyrem® | Phase 3 | Fibromyalgia | - |
Xyrem | Phase 3 | Narcolepsy | - |
Dordaviprone (ONC201) | Phase 3 | H3 K27M | - |
Sodium Oxybate | Phase 3 | Essential Tremor | - |
IM JZP-458 | Phase 3 | Acute Lymphoblastic Leukemia | - |
GW-1000-02 | Phase 3 | Pain | - |
Sodium Oxybate & 6 Tablets | Phase 3 | Fibromyalgia | - |
Zanidatamab | Phase 3 | HER2-positive Breast Cancer | - |
Gemcitabine | Phase 3 | Metastatic HER2-positive Breast Cancer | - |
Capecitabine | Phase 3 | Gastric Neoplasms | - |
CPX-351 | Phase 3 | Acute Myeloid Leukemia (AML) | - |
Pembrolizumab | Phase 3 | Biliary Tract Cancer | - |
7+3 (cytarabine and daunorubicin) | Phase 3 | High Risk Acute Myeloid Leukemia | - |
Defibrotide | Phase 3 | Severe Hepatic Veno-Occlusive Disease | - |
experimental anti-anxiety drug | Phase 3 | Anxiety Disorder | - |
GW-2000-02 | Phase 3 | Pain | - |
Xyrem (sodium oxybate) oral solution | Phase 3 | Fibromyalgia | - |
a benzodiazepine drug | Phase 3 | Anxiety Disorder | - |
JZP-258 | Phase 3 | Idiopathic Hypersomnia | - |
THC Alone | Phase 3 | Palliative Care | - |
GWP42003-P | Phase 3 | Epilepsy | - |
GWP42003-P 20 mg/kg/day Dose | Phase 3 | Epilepsy | - |
Sativex® | Phase 3 | Pain | - |
JZP-110 | Phase 3 | Obstructive Sleep Apnea | - |
Suvecaltamide | Phase 2 | Parkinson Disease | - |
Dociparstat sodium | Phase 2 | Acute Myeloid Leukemia | - |
Palbociclib | Phase 2 | HER2+/HR+ Breast Cancer | - |
Lurbinectedin | Phase 2 | Refractory Ewing Sarcoma | - |
GWP42006 | Phase 2 | Epilepsy | - |
ZW25 (Zanidatamab) | Phase 2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | - |
asparaginase Erwinia chrysanthemi | Phase 2 | Acute Lymphoblastic Leukemia | - |
GWP42003 | Phase 2 | Schizophrenia | - |
Evorpacept | Phase 2 | HER2-expressing Cancers | - |
Clobazam | Phase 2 | Epilepsy | - |
Daunorubicin | Phase 2 | Acute Myeloid Leukemia | - |
GWP42004 | Phase 2 | Dyslipidemias | - |
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection | Phase 2 | Colorectal Neoplasms | - |
CX-8998 | Phase 2 | Epilepsy | - |
JZP385 | Phase 2 | Essential Tremor | - |
Clonazepam | Phase 2 | Epilepsy | - |
GWP42003-P 5 mg/kg/day Dose | Phase 2 | Epilepsy | - |
Standard of Care | Phase 2 | Graft-versus-host Disease | - |
Intensive Salvage Therapy | Phase 2 | Acute Myeloid Leukemia | - |
JZP150 | Phase 2 | Post Traumatic Stress Disorder | - |
ADX-N05 | Phase 2 | Narcolepsy | - |
Regulatory & News
Approvals, filings, and latest developments